Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
Open accessAbstract
Background— Lipoprotein (a) [Lp(a)] is a genetic cardiovascular risk factor that preferentially binds oxidized phospholipids (OxPL) in plasma. There is a lack of therapeutic agents that reduce plasma Lp(a) levels. Methods and Results— Transgenic mice overexpressing human apolipoprotein B-100 (h-apoB-100 [h-apoB mice]) or h-apoB-100 plus human apo(a) to generate genuine Lp(a) particles [Lp(a) mice] were treated with the antisense oligonucleotide mipomersen directed to h-apoB-100 mRNA or control antisense oligonucleotide for 11 weeks by intraperitoneal injection. Mice were then followed up for an additional 10 weeks off therapy. Lp(a) levels [apo(a) bound to apoB-100] and apo(a) levels [“free” apo(a) plus apo(a) bound to apoB-100] were measured by chemiluminescent enzyme-linked immunoassay and commercial assays, respectively. The content of OxPL on h-apoB-100 particles (OxPL/h-apoB) was measured by capturing h-apoB-100 in microtiter wells and detecting OxPL by antibody E06. As expected, mipomersen significantly reduced plasma h-apoB-100 levels in both groups of mice. In Lp(a) mice, mipomersen significantly reduced Lp(a) levels by ≈75% compared with baseline ( P <0.0001) but had no effect on apo(a) levels or hepatic apo(a) mRNA expression. OxPL/h-apoB levels were much higher at baseline in Lp(a) mice compared with h-ApoB mice ( P <0.0001) but decreased in a time-dependent fashion with mipomersen. There was no effect of the control antisense oligonucleotide on lipoprotein levels or oxidative parameters. Conclusions— Mipomersen significantly reduced Lp(a) and OxPL/apoB levels in Lp(a) mice. The present study demonstrates that h-apoB-100 is a limiting factor in Lp(a) particle synthesis in this Lp(a) transgenic model. If applicable to humans, mipomersen may represent a novel therapeutic approach to reducing Lp(a) levels and their associated OxPL.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pre-clinical studies confirmed the proof of concept that antisense oligonucleotides specifically lower Lp(a) levels.
“Pre-clinical studies confirmed the concept (proof of concept) that antisense oligonucleotides specifically lower Lp(a) levels [197, 198].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [197]
The Results section ('Effect of Mipomersen on H-ApoB-100 levels and Lp(a) Levels') reports a significant decline in Lp(a) in transgenic mice treated with an antisense oligonucleotide, supporting the preclinical proof of concept. But 'Effect of Mipomersen on Lipoprotein Levels and Composition' also reports an approximately 75% reduction in LDL: the treatment targeted apoB-100, not Lp(a) specifically. (LLM, conf=0.87)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 36 · Cited by 156
- Authors
- Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Circulation
- Published
- 2008-08-12
- Volume
- 118
- Issue
- 7
- Pages
- 743-753
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2053513183
- Cited by
- 156
- References
- 36
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 11 · 2022: 7 · 2021: 5 · 2020: 3 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 14 · 2015: 13 · 2014: 11 · 2013: 12 · 2012: 13
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein B-100, antisense oligonucleotides, mipomersen, oxidized phospholipids, apolipoprotein(a), cardiovascular risk factors, lipid-lowering therapy, RNA interference
- MeSH terms
- Animals, Apolipoproteins A, Autoantibodies, Cholesterol, Humans, Malondialdehyde, Mice, Inbred C57BL, Mice, Transgenic, Oligonucleotides, Oxidation-Reduction, Phospholipids, RNA, Messenger, Transfection, Triglycerides, Oligonucleotides, Antisense, Lipoprotein(a), Mice, Apolipoprotein B-100
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
